Skip to content
SEC filings edition: Friday, November 13, 2026 · 767 companies with filings Publisher's serviceBoardeon, your AI board · Hire your board →
Monday, November 16, 2026Every business day from SEC EDGAR
SEC EDGAR · Nov 13, 2026 1bankruptcies 11delisting notices 12late filings 43leadership changes 6IPO filings 199private raises 90earnings releases
Company page · CIK 2044725 · EVMN

Evommune, Inc.

Filing with the SEC SEC-reporting company Palo Alto, CA NYSE
An email when it files something new with the SEC. Your account

What this means

  • Net loss in 2025Net loss of $68.9M for the year (2024: −$66.8M).

What to do next

Guides from the Companies Daily newsroom, picked for what the register shows.

Financials from XBRL

Calendar-year frame20252024
Revenue$13M$7M
Net income (loss)−$68.9M−$66.8M
Total assets$225M$76.1M
Total liabilities$19.4M$28.5M
Stockholders’ equity$206M−$144M
Cash and equivalents$44.1M$16.3M

From XBRL data the company filed with the SEC (data.sec.gov frames, US GAAP, US dollars). A frame aligns the fiscal year with the calendar year closest to it; this company’s fiscal year ends December 31. Check the annual report for the exact figures and periods.

Name as filed
Evommune, Inc.
CIK
0002044725
Tickers
EVMN
Kind of filer
SEC-reporting company
Emerging growth company
Status
Filing with the SEC
State of incorporation
Delaware
Business address
Palo Alto, California
Industry (SIC)
2834 · Pharmaceutical preparations
Industry: D · Manufacturing →
Fiscal year ends
December 31
Last annual report
10-K for the period ended Dec 31, 2025
Last quarterly report
10-Q for the quarter ended Sep 30, 2026
Bankruptcy reported
Not in our data
Last edition event
Nov 12, 2026

Filing history

Newest first: the filings we classify (8-K items, late filing notices, delistings, deregistration, IPO registrations, Schedule 13D, Form D, annual and quarterly reports), from Jan 1, 2023. All documents, including those we do not classify, are in the EDGAR filing index.

  • Quarterly report filed: 10-Q for the quarter ended Sep 30, 2026
    Form 10-Q · filed Nov 12, 2026 · filing · edition of Nov 12, 2026
  • Results announced
    Form 8-K · items 2.02, 7.01, 9.01 · filed Nov 12, 2026 · filing · edition of Nov 12, 2026
  • Results announced
    Form 8-K · items 2.02, 9.01 · filed Aug 6, 2026 · filing
  • Quarterly report filed: 10-Q for the quarter ended Jun 30, 2026
    Form 10-Q · filed Aug 6, 2026 · filing
  • Results announced
    Form 8-K · items 2.02, 7.01 · filed May 7, 2026 · filing
  • Quarterly report filed: 10-Q for the quarter ended Mar 31, 2026
    Form 10-Q · filed May 7, 2026 · filing
  • IPO registration filed: Registration statement (S-1)
    Form S-1 · filed Apr 17, 2026 · filing
  • Results announced
    Form 8-K · items 2.02 · filed Mar 5, 2026 · filing
  • Annual report (10-K): 10-K for the period ended Dec 31, 2025
    Form 10-K · filed Mar 5, 2026 · filing
  • Results announced
    Form 8-K · items 2.02, 9.01 · filed Dec 11, 2025 · filing
  • Quarterly report filed: 10-Q for the quarter ended Sep 30, 2025
    Form 10-Q · filed Dec 11, 2025 · filing
  • Stake of 5% or more with intent to influence: Schedule 13D: stake of 5% or more
    Form SCHEDULE 13D · filed Nov 17, 2025 · filing
  • Stake of 5% or more with intent to influence: Schedule 13D: stake of 5% or more
    Form SCHEDULE 13D · filed Nov 14, 2025 · filing
  • IPO prospectus (424B4): Final prospectus (424B4)
    Form 424B4 · filed Nov 6, 2025 · filing
  • IPO registration filed: Registration statement (S-1)
    Form S-1 · filed Oct 9, 2025 · filing
  • Private raise (Form D)
    Form D · items 06b · filed Jan 8, 2025 · filing
  • Private raise (Form D)
    Form D · items 06b · filed Jan 8, 2025 · filing
  • Private raise (Form D)
    Form D · items 06b · filed Jan 8, 2025 · filing
  • Private raise (Form D)
    Form D · items 06b · filed Jan 7, 2025 · filing